The company was chosen due to the development of a solution that will help as part of the fight against the rising threat of bacterial resistance to antibiotics
MeMed company, which develops a blood test and an innovative point-of-care measurement platform that differentiates between bacterial and viral infection, announced today that it has been selected by the World Economic Forum as a Technology Pioneer for 2019, one of 56 companies selected from around the world.
The technology pioneer community of the World Economic Forum consists of companies in various stages of existence from around the world, which are expected to bring significant change in a wide variety of fields and which will have a substantial impact on society and the business world. The World Economic Forum selected MeMed for its groundbreaking approach, which helps doctors make more informed decisions around the administration of antibiotics and the use of additional tests and treatments in patients with acute infectious disease. In this way, MeMed contributes to the fight to reduce the spread of antibiotic-resistant bacterial strains.
"We are excited to welcome MeMed to the group of innovative technology pioneers of 2019" said Fulvia Montresor, leader of technology pioneers on behalf of the World Economic Forum. "MeMed and its members in the community that were selected this year, are leaders in the development and use of innovative technologies with the aim of stimulating a transformation in their field. We see tremendous potential in the power of these companies to develop solutions to global challenges and improve the face of society in the years to come."
MeMed's vision is to translate the complex signals of the immune system into simple diagnostic insights, which can be used to completely change the way infectious diseases and other inflammatory syndromes are diagnosed and treated, thereby benefiting patients both at the individual level and at the level of the entire population. The company's groundbreaking test, MeMed BV™, is based on measuring proteins in the blood, which are related to the immune system, and quickly and reliably determines whether an infection is caused by a bacterium that will respond to antibiotic treatment, or by a virus, for which there is no point in such treatment. The high level of accuracy of the MeMed BV™ test has been proven in several double-blind clinical studies conducted around the world.
"It is an honor for us to be recognized as a technological pioneer for 2019 by the World Economic Forum and to join a community of companies with a vision to improve life on a global scale," said Dr. Eran Aden, founder and CEO of MeMed. "Our goal is to develop solutions to the biggest health challenges in the world, and to bring about a significant improvement in the lives of patients, and this also by treating the issue of bacterial resistance to antibiotics."
Dr. Kafir Oved, founder and VP of Technology of MeMed, added: "We are excited about the recognition by the World Economic Forum, which emphasizes our commitment to allow broad access to fast and efficient diagnostic tests, and to significantly reduce the phenomenon of overuse of antibiotics. These are critical steps designed to prevent the spread of drug-resistant bacteria, with the aim of improving public health."
The phenomenon of the spread of antibiotic-resistant bacterial strains causes approximately 700,000 deaths worldwide each year, a figure that is expected to increase to 10 million deaths per year by 2050, according to a United Nations report published in April 2019. To accelerate efforts to combat the threat This, MeMed has also developed the MeMed Key™, a platform for measuring proteins with a high level of accuracy at the point of care and allows receiving results for the MeMed BV™ test within 15 minutes. The platform will also be used to perform additional MeMed breakthrough diagnostic tests, which are currently in development and which will provide solutions to a wide range of clinical challenges by combining machine learning with measurements of the immune response.
MeMed joins a diverse group of technology pioneers for 2019 selected by an international committee of more than 59 academics, entrepreneurs, venture capital fund leaders and corporate executives brought together for this purpose by the World Economic Forum. In the group of companies that received a badge of honor for technological pioneers in the past, there are companies such as Airbnb, Editas Medicine, Spotify, Google, Foundation Medicine, Kickstarter, Mozilla, Proteus Digital Health, and Twitter.
More of the topic in Hayadan:
One response
exciting!